Oppenheimer & Co. Inc. grew its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 11.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 34,000 shares of the biotechnology company’s stock after purchasing an additional 3,600 shares during the period. Oppenheimer & Co. Inc.’s holdings in Ironwood Pharmaceuticals were worth $536,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Rothschild Asset Management Inc. raised its holdings in Ironwood Pharmaceuticals by 5.6% in the 3rd quarter. Rothschild Asset Management Inc. now owns 1,265,471 shares of the biotechnology company’s stock worth $19,956,000 after acquiring an additional 66,906 shares during the last quarter. Artal Group S.A. raised its holdings in Ironwood Pharmaceuticals by 32.4% in the 3rd quarter. Artal Group S.A. now owns 816,879 shares of the biotechnology company’s stock worth $12,882,000 after acquiring an additional 200,000 shares during the last quarter. SG Americas Securities LLC raised its holdings in Ironwood Pharmaceuticals by 122.3% in the 3rd quarter. SG Americas Securities LLC now owns 28,187 shares of the biotechnology company’s stock worth $445,000 after acquiring an additional 15,505 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Ironwood Pharmaceuticals by 40.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 143,082 shares of the biotechnology company’s stock worth $2,256,000 after acquiring an additional 41,406 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Ironwood Pharmaceuticals by 3.5% in the 3rd quarter. New York State Common Retirement Fund now owns 1,404,659 shares of the biotechnology company’s stock worth $22,151,000 after acquiring an additional 47,675 shares during the last quarter.

IRWD has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Mizuho restated a “buy” rating and issued a $20.00 price objective (down from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. Credit Suisse Group began coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, November 27th. They set a “buy” rating and a $19.00 target price for the company. Finally, Cowen set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.38.

Shares of Ironwood Pharmaceuticals, Inc. (IRWD) opened at $17.32 on Friday. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. Ironwood Pharmaceuticals, Inc. has a 12 month low of $13.43 and a 12 month high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. The business had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The company’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.18) EPS. equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Oppenheimer & Co. Inc. Acquires 3,600 Shares of Ironwood Pharmaceuticals, Inc. (IRWD)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/02/oppenheimer-co-inc-acquires-3600-shares-of-ironwood-pharmaceuticals-inc-irwd.html.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.